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also plays an important role in affecting tumor 
response to ionizing radiation [1,2]. However, studying 
the complex and interdependent relationship between 
the response of tumor cells and their vasculature in 
preclinical in vivo models has been a major challenge. 
To address this, we developed a novel experimental 
platform to study, non-invasively, the radiobiological 
response of tumors and their vascular at structural, 
functional, and cellular levels in solid tumors in vivo. 
Methods: Our platform consists of a murine dorsal 
skinfold window chamber (WC) tumor model, a small 
animal x-ray microirradiator and multimodal intravital 
imaging modalities (confocal fluorescence microscopy 
(CFM) and speckle variance optical coherence 
tomography (svOCT)). A DsRed-Me180 human cervical 
carcinoma cell line was implanted in the dorsal skinfold 
at the time of WC surgery and was grown for 1 week, 
followed by irradiation (single dose 30 Gy) and 
multimodal microscopic imaging of multiple tumor 
components simultaneously in vivo for up to 3 weeks. 
In addition, laser capture microdissection (LCM) of ex 
vivo tissues was used to prepare tissues for mRNA 
microarray to investigate the corresponding RT-
induced transcriptomic modifications in irradiated 
tumors. 
Results: CFM was used to provide morphological, 
structural and functional information about vessels 
based on blood perfusion of the fluorescent dextran 
agent (FITC-Dextran), while svOCT was used to 
provide spatiotemporally correlated maps of patent 
vascular structures without any contrast agents. Our 
data showed that a single fraction of 30 Gy to the tumor 
caused functional disruption in both large vasculature 
(>70 μm) and capillary (<40 μm) sized 
microvasculature, while leaving most of the large 
vasculature structurally intact. These hemodynamic 
effects were most prominent between days 8-14 
following treatment (Figure 1). Moreover, we observed 
an increase in microvascular density after day 14 to a 
level significantly higher than pre-treatment, possibly 
indicating RT-induced neovascularization. The 
functional disruption of irradiated vessels could be 
attributed to RT-induced platelet thrombosis, which 
was observed as early as 1h after RT. We also observed 
a decrease in the coverage of perivascular cells around 
tumor vasculature 4 to 8 days after RT. Moreover, these 
RT-induced structural, functional and cellular changes 
in the microvasculature in vivo were accompanied by 
alterations in gene expression. Briefly, 4 days after RT, 
vascular-related genes (Vegfa, Mmp9 and Mmp2) were 
up-regulated in the irradiated tumor, while smooth 
muscle and pericyte-related genes (Des, Myh4, Ttn and 
Mybpc2) were down-regulated, which correlated well 
with our in vivo imaging data. A number of eukaryotic 
initiation factors were also down-regulated, suggesting 
translational machinery dysregulation preceding tumor 
cell apoptosis. 
Conclusions: Our multimodal platform overcomes 
previous technical limitations in preclinical studies of 
radiobiological response: i) the microirradiator enabled 
precise focal treatment of small tumors in the dorsal 
skinfold WC with a controlled dose, and ii) the WC 
model allowed for simultaneous monitoring of multiple 
tumor components with single-cell resolution using 
CFM, and for visualization of the vascular network at 
the capillary level using svOCT. The major advantage 
of our approach over conventional xenograft models is 
the ability to study spatio-temporally specific radiation 
response of interdependent components within solid 
tumor longitudinally at high resolution in vivo. Lastly, 
the additional capability of spatially-localized genomic 
analysis was used to correlate genetic changes with in 
vivo optical imaging data obtained longitudinally, 
allowing us to gain new insights into possible 
mechanisms of RT-induced modifications. Thus, our 
results demonstrate the capability of this new 
preclinical experimental platform to enable 
quantitative, high-resolution and multiparametric 
intravital optical imaging of complex and dynamic 




Figure 1: Longitudinal optical imaging of an irradiated 
tumor using fluorescence confocal microscopy (top: 
FITC-Dextran in green, DsRed-Me180 in red) and 
depth-encoded svOCT (bottom), demonstrating 
dynamic functional and structural changes in tumor 
vasculature following treatment with single dose 30 Gy 
RT. 
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Introduction: The EORTC dummy run (DR) was 
implemented in 1987 to address early signs that 
institutions could not meet minimum technical 
requirements for Radiation Oncology Group (ROG) 
trials. After central review of a DR (practice) case, 
reviewer comments are sent to local principal 
investigators (PIs). This feedback is ideally applied to 
subsequent protocol patients’ RT planning. The goal of 
the individual case review (ICR), originating in 1989, is 
systematic assessment of treatment received to evaluate 
actual protocol compliance. Since 1991, DR and ICR 
results have been published for trials on cancers of the 
breast, prostate, brain and head and neck. Our objective 
was to review EORTC radiotherapy (RT) quality 
assurance (QA) data to investigate whether completion 
of a DR increases success rates for other QA procedures 
or impacts patient outcomes. 
Methods: EORTC protocols closed to recruitment were 
reviewed for inclusion of a DR procedure. Candidate 
studies were randomized phase III studies in which the 
ROG managed trial QART. Data was collected, 
evaluated, translated, reformatted, and collated into 
databases. If a DR case grade was either acceptable or 
  ICTR-PHE 2012 S63 
minor deviation (at first submission), this was sufficient 
for authorization to participate in a trial and was 
considered a success (at first attempt).  A DR was 
classified as a failure if issues were found which 
required correction and re-submission. Trials with a DR 
procedure were reviewed for ICR results and mature 
clinical outcomes. Similar to DR, ICR datasets were 
graded overall as acceptable, major or minor violation. 
Fisher’s exact test was used to characterize potential 
correlations and the Mantel-Haenszel statistic provided 
estimates of pooled odds ratios (OR).  
Results: 25 closed ROG protocols implemented a DR. 
Raw data were available in 12, of which success at first 
attempt could be reconstructed in six, and ICR results 
were known for three (Table 1). The proportion of 
institutions successful at first DR attempt varied from 
5.6% to 68.8%. Of those who previously participated in 
a DR, between 8.3-76.9% were successful on the first 
attempt in the current trial. There was a significant 
correlation between past DR participation and success 
at first attempt for the 22991 trial (p=0.04); this was a 
trend for 10981 (p=0.06), and for the remainder, there 
was no correlation. Institutions were 3.2 times more 
likely to be successful at first DR attempt if they had 
previously participated in this procedure (95% CI 1.73-
5.93; p=0.0002).  Of all patients reviewed during an 
ICR, the proportion from institutions successful at DR 
first attempt was on average 62.0%. Of these, 
approximately half (52.3%) had an overall ICR grade of 
acceptable. There was a significant correlation for the 
22991 trial only (p=0.03). Pooled OR was 1.69 (95% CI 
0.97-2.95; p=0.06). Repeating this analysis including 
patients receiving an ICR grade of either acceptable or 
minor deviation did not change the conclusions.  
Mature clinical outcomes were available for the 22911 
trial only; median follow-up for all patients was 10.6 
years. 389 patients from 26/36 participating institutions 
were included in this analysis. For patients irradiated 
by a site which participated in the DR, 5 year 
progression-free survival (PFS) was 81.6% (95%CI 76.7-
85.4%), compared to 79.8% (95%CI 69.1-87.1%) for 
patients from non-participating sites. This difference 
was, however, not significant on either univariate (HR 
0.91; 95%CI 0.65-1.45; p=0.88) or multivariate analysis 
(HR 1.09; 95%CI 0.70-1.68; p=0.70) adjusted for 
statistically significant patient and disease factors (age, 
nerve-sparing surgical procedure, post-operative PSA, 
seminal vesicle invasion).  
Conclusions:  In this review of two decades of data 
from the EORTC ROG, institutions which previously 
participated in a DR were significantly more likely to 
be successful at subsequent first DR attempts. With the 
exception of the 22991 prostate trial, this correlation 
was not significant for any specific trial, likely due to 
small sample sizes. For the 22991 trial, sites which were 
successful at first DR attempt were also significantly 
more likely to deliver protocol-compliant RT, based on 
results of the ICR.  In the 22911 trial, however, a 
significant effect of DR participation on 5yr PFS could 
not be demonstrated.  
 
Table 1. Summary of trials included in analysis. *Data 
available on DR success at first attempt. ¶ICR results 
available. §Trial not centrally activated or did not 
complete planned accrual. Abbreviations: chemo – 
chemotherapy; CUP – carcinoma of unknown primary; 
H&N – head and neck; LN - lymph node; postop - 
postoperative; RT - radiotherapy.  
 
Trial DR Completed Trial Randomization 
Prostate   
22863 1991-1992 Pelvic RT vs pelvic RT + 
hormone therapy 
22911 1998-2000 Immediate postop RT vs RT at 
local relapse 
22961 2001-2003 RT + 6 months concurrent 
hormone therapy +/- 2.5 years 
adjuvant hormone therapy 
22991*¶ 2001-2006 RT +/- concurrent hormone 
therapy in early stage disease 
Breast   
22881 1989-1995 Breast RT boost vs no boost 
post-segmental resection 
22922*¶ 1996-2002 Internal mammary LN RT vs 
no internal mammary RT 
10981* 2001-2009 Axilla RT vs surgery after 
positive sentinel LN procedure 
H&N   
22931 1994-1997 Postoperative chemoRT vs RT 
alone 
24001*§ 2003-2004 Extensive H&N RT vs 
ipsilateral neck RT only for 
CUP 
22071*§ 2010-2011 Postop chemoRT +/- 
concurrent anti-EGFR 
antibody 
Brain   
22972§ 1999-2001 Stereotactic boost vs no boost 
for high grade glioma 
22033*¶ 2006-2010 Primary chemotherapy vs RT 
for low grade glioma 
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Introduction: Central review of radiotherapy (RT) 
delivery within multicentre clinical trials was initiated 
in the early 1970’s in the USA. Early quality assurance 
(QA) performed by the CALGB and other clinical trial 
groups revealed non-uniformity of treatment strategies. 
Aside from the suggestion of increased patient 
evaluability with central QA office intervention, initial 
publications often focused on metrics related to 
process, logistics and timing. The objective of this work 
was to review available evidence for correlation of RT 
quality with clinical outcomes within multicentre 
cooperative group clinical trials.  
Methods: An OVID medline search was performed 
restricted to the English language, but with no 
restriction on date of publication. Candidate 
multicentre studies accrued adults only, were led by 
any cooperative group, and described central subjective 
+/- objective assessment of RT protocol compliance 
(quality). The QA publications and, where necessary, 
other papers describing trial clinical results were 
evaluated. Data abstracted included method of central 
